A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma.

Ciara M Kelly Li-Xuan Qin Karissa A Whiting Allison L Richards Viswatej Avutu Jason E Chan Ping Chi Mark A Dickson Mrinal M Gounder Mary Louise Keohan Sujana Movva Benjamin A Nacev Evan Rosenbaum Travis E Adamson Samuel Singer Madalyn G Neuwirth Aimee M Crago Sam S Yoon Sinchun Hwang Joseph Patrick Erinjeri Cristina R Antonescu William D Tap Sandra P D' Angelo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved.

Keyphrases

advanced non small cell lung cancer
open label
clinical trial
randomized controlled trial
tyrosine kinase